80 results on '"F. Méchaï"'
Search Results
2. Tuberculosis treatment outcomes among precarious patients in France
- Author
-
F, Méchaï, D, Bachelet, L, Han, M, Dubert, M, Parisey, H, Cordel, A, Bourgarit, C, Bertrac, S, Chauveau, T, Billard-Pomares, E, Carbonnelle, O, Bouchaud, Y, Yazdanpanah, N, Vignier, and C, Laouénan
- Subjects
Adult ,Cohort Studies ,Treatment Outcome ,Infectious Diseases ,Antitubercular Agents ,Humans ,Tuberculosis ,HIV Infections ,Prospective Studies ,France ,Child ,Aged - Abstract
Patients lost to follow-up and treatment failure in tuberculosis disease (TB) are major public health issues. In the absence of appropriate treatment, approximately 70 % of smear-positive patients will die within 10 years of disease progression. This study, conducted in the French region with the highest incidence, aimed to assess tuberculosis treatment outcomes and its determinants.A prospective, multicenter cohort study (CO1TB) of adults and children treated for TB was conducted in four hospitals in the North of Paris. Treatment outcome at 1 year and associated socioeconomic and clinical factors were studied by multivariate logistic regression.Among 145 TB cases included from May 2018 to January 2020, patients were mainly born abroad and most lived in difficult socioeconomic conditions. During treatment, 25/145 (17 %) patients experienced adverse effects, which were not significantly associated with discontinuation of treatment (p = 0.99). At 1 year, 114 (78 %) had completed treatments, 26 (19 %) were lost to follow-up, three (2.1 %) were still being treated and two (1.4 %) had died. In the multivariate analysis, a history of TB was significantly associated with unfavorable treatment outcome (aOR = 5.3, 95 %CI (1.5;18.6) and a trend towards significance (p 0.2) was observed among patients aged under 24 years (aOR = 2.9, 95 %-CI 0.95;8.5).In this precarious population, socioeconomic conditions were not found to be associated with unfavorable treatment outcome, whereas history of tuberculosis and young age played a role. Increased monitoring is thus required for these patients.
- Published
- 2022
- Full Text
- View/download PDF
3. Screening for active and latent TB among migrants in France
- Author
-
C Charlois, G Ibanez, S Hargreaves, L Luan, P Fraisse, M. Mechain, H Cordel, F Méchaï, and Nicolas Vignier
- Subjects
Transients and Migrants ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Tb screening ,Primary care ,Health outcomes ,Europe ,Secondary care ,Infectious Diseases ,Latent Tuberculosis ,Family medicine ,Active tb ,medicine ,Humans ,Mass Screening ,France ,High incidence ,Child ,business - Abstract
SETTING: Migrants to Europe face a disproportionate burden of infections, including TB, yet little is known about the approach taken by primary and secondary care providers to screening and treatment. We therefore explored policy and practice relating to screening of active TB and latent TB infection (LTBI) in France.METHODS: We conducted an online national survey of French primary and secondary care physicians regarding their practices in relation to TB/LTBI screening among migrants.RESULTS: 367 physicians responded to the questionnaire among which 195 (53.1%) were primary care physicians, 126 (34.3%) were TB specialists in secondary care, and 46 (12.5%) other physicians; 303 (85.5%) were involved daily in the care of migrants. Most respondents recommended systematic TB screening with chest X-ray for migrants from medium and high-incidence countries (71.9%). Primary care physicians were less likely to offer screening than physicians in other settings (aOR 0.21, 95% CI 0.09–0.48). 220 (61.8%) offered LTBI screening for children (CONCLUSION: Improving awareness on TB screening is a critical next step to improve health outcomes in migrant groups and meet regional targets for tackling TB.
- Published
- 2021
- Full Text
- View/download PDF
4. Tuberculose pulmonaire : la valeur du CT du test Xpert® MTB/RIF peut-elle prédire la contagiosité ?
- Author
-
F. Méchaï, N. Vignier, O. Bouchaud, E. Carbonnelle, and T. Billard-Pomares
- Published
- 2023
- Full Text
- View/download PDF
5. Intra-abdominal abscesses: Microbiological epidemiology and empirical antibiotherapy
- Author
-
F, Méchaï, A, Kolakowska, E, Carbonnelle, O, Bouchaud, C, Tresallet, and F, Jaureguy
- Subjects
Infectious Diseases - Abstract
Data on the microbiological epidemiology of Intra-Abdominal Abscesses (IAAs) are very scarce. We aimed to study the microbiological epidemiology of these infections in order to optimize empirical antibiotic therapy.Between January 2015 and December 2020, we retrospectively analyzed all IAAs files in our hospital. Clinical and microbiological data such as antibiotic susceptibilities were collected.We studied 243 IAA cases. All in all, 139 (57.2%) IAAs were healthcare-associated and 201 (82.7%) were drained. The highest risk situations for IAAs were appendicitis (n = 69) and diverticulitis (n = 37). Out of the 163 microbiologically documented infections, 136 (81.9%) were polymicrobial. Enterobacterales (n = 192, 36.1%), Enterococcus sp. (n = 84, 17.6%) and anaerobes (n = 66, 16.1%) were the most frequently identified bacteria. Gram-negative bacteria were susceptible to amoxicillin-acid clavulanic, piperacillin-tazobactam, cefotaxime, meropenem in 55.2%, 84.9%, 77.6% and 99.5% of cases, respectively. Concerning Gram-positive bacteria, the susceptibility rate was 81.8% for amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem, and decreased to 63.4% for cefotaxime.This study highlights the polymicrobial profile of IAAs and their low susceptibility to amoxicillin and clavulanic acid. The piperacillin-tazobactam association remained the most appropriate empirical antibiotic therapy.
- Published
- 2023
- Full Text
- View/download PDF
6. Bactériurie asymptomatique avant biothérapie : faut-il traiter ?
- Author
-
M. Lacroix, S. Johanna, N. Hassold, P. Cruaud, O. Bouchaud, F. Méchaï, Violaine Walewski, and N. Saidenberg-Kermanac’h
- Subjects
Rheumatology - Published
- 2021
- Full Text
- View/download PDF
7. Screening for tuberculosis among newly arrived migrants in France. Results from a practice study
- Author
-
C Charlois, L. Luan, M. Lachatre, M. Mechain, F Méchaï, J Figoni, H Cordel, Nicolas Vignier, and H. Leroy
- Subjects
medicine.medical_specialty ,Geography ,Tuberculosis ,Family medicine ,Public Health, Environmental and Occupational Health ,medicine ,medicine.disease - Abstract
Background Screening of active and latent tuberculosis among migrants is a public health concern but physicians’ practices are poorly known. The study aimed to evaluate physicians’ practices in France. Methods A national survey of physicians’ practices about infectious diseases prevention among migrants was conducted in 2017-2018 and broadcasted by several scientific societies. Results In total, 367 physicians answered; 53.1% were primary care physicians, 34.3% “TB involved physicians”, and 85.5% were involved daily with migrants. Screening by chest X ray is recommended by 84.8%, 71.9% and 38.4% of participants for migrants from high- (>100 cases/100,000 p.a.), medium- (> 50/100,000), and low-incidence countries respectively. One physician in two declares considering migration conditions in his/her decision of screening migrants from low incidence countries. Primary care physicians are less likely to offer screening (aOR= 0.21[0.09-0.48], p < 0.001). About screening prescription, only 55.6% consider it their responsibility. TB control centres are designated by 56.7% of respondents. Concerning screening for latent tuberculosis infection (LTBI), 61.8% and 34.0% offered screening for children under the age of 15 and for all migrants (adults and children) from high incidence countries respectively; physicians working in Paris and its region being less likely to offer it (aOR=0.45 [0.28-0.71], p = 0.001 and aOR=0.43 [0.27-0.69] p = 0.001 respectively). Among those screening children, 88.1% recommend treatment if facing a positive result, most often with a 3-month isoniazid rifampicin double therapy, and 11.4% offer follow up alone. Conclusions Physicians’ practices in France regarding screening of tuberculosis among migrants are heterogeneous. Which population should be targeted for LTBI screening remains unclear in the context of contradictory national and international recommendations. The results of our study raise the issue of knowledge, and adherence to these guidelines. Key messages Physicians’ practices in France concerning active and latent tuberculosis screening among newly arrived migrants are heterogeneous. Many physicians involved in migrants’ care ignore or do not adhere to current national guidelines, especially concerning LTBI screening among newly arrived migrants.
- Published
- 2019
- Full Text
- View/download PDF
8. Pulmonary tuberculosis: Evaluation of current diagnostic strategy
- Author
-
S.B. Gressens, H. Leboité, Typhaine Billard-Pomares, E. Carbonnelle, P. Cruaud, Olivier Bouchaud, and F. Méchaï
- Subjects
Adult ,Male ,medicine.medical_specialty ,Tuberculosis ,Sensitivity and Specificity ,Specimen Handling ,03 medical and health sciences ,Tuberculosis diagnosis ,Internal medicine ,Medicine ,Humans ,Prospective cohort study ,Tuberculosis, Pulmonary ,Retrospective Studies ,0303 health sciences ,030306 microbiology ,business.industry ,Sputum ,Retrospective cohort study ,Nucleic acid amplification technique ,Gold standard (test) ,Mycobacterium tuberculosis ,Middle Aged ,medicine.disease ,Infectious Diseases ,Early Diagnosis ,Specimen collection ,Female ,France ,medicine.symptom ,business ,Nucleic Acid Amplification Techniques ,Algorithms - Abstract
To identify tools that will result in faster diagnosis, making the current pulmonary tuberculosis strategy more efficient.A 4-year (2015-2018) retrospective study. The gold standard for diagnosis was a positive culture from a respiratory specimen. All sputum, fibroscopy and post-fibroscopy specimens (for smear negative patients) were collected. Each specimen was analyzed through smear examination and culture. All nucleic acid amplification testing results were included. Analyses looked at the incremental yield of positive cases of each successive specimen collection, and time to diagnosis.A total of 354 patients had at least one positive culture. Sputum allowed a diagnosis in 92% of cases (including a gain in sensitivity of around 7% for the third sputum specimen), with 160 smear-positive patients (45%). Among smear-negative patients, 109 underwent a fibroscopy procedure (culture sensitivity of 75%), and 59 had a post-fibroscopy specimen collected, which together identified the rest of the patients (8%). Molecular testing was used in 237 specimens. Median time to diagnosis was 11 days, which was significantly reduced among smear-negative patients when molecular testing was used (P0.001). Shortening the delay between sputum specimen collections did not alter procedure sensitivity.We identified several aspects of the French tuberculosis diagnosis algorithm that could be improved, and posed the basis for a prospective study. Centers in higher incidence areas could benefit from a dedicated, predefined procedure exploring suspicions of tuberculosis. A high suspicion score of tuberculosis could drive the reasoned use of molecular testing in such settings.
- Published
- 2019
9. Management and treatment of uncomplicated imported malaria in adults. Update of the French malaria clinical guidelines
- Author
-
C. Rapp, F. Méchaï, J.F. Faucher, Emmanuel Bottieau, Loïc Epelboin, Sophie Matheron, Denis Malvy, Eric Caumes, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Hôpital d'Instruction des Armées Begin, Service de Santé des Armées, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Adult ,medicine.medical_specialty ,business.industry ,030231 tropical medicine ,MEDLINE ,medicine.disease ,Malaria ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Communicable Diseases, Imported ,Practice Guidelines as Topic ,parasitic diseases ,medicine ,Humans ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,France ,030212 general & internal medicine ,Intensive care medicine ,business ,Imported malaria - Abstract
International audience; The diagnosis of malaria should always be considered in travelers returning from an endemic area and presenting with fever or a history of fever, either isolated or combined with other general, digestive, and/or respiratory symptoms, even if appropriate chemoprophylaxis was used.• Outpatient management of uncomplicated Plasmodium falciparum malaria may be implemented if precise clinical and biological criteria are met and if medical follow-up is possible.• Admission to hospital is recommended for individuals at risk of complications (young children and elderly, comorbidity, pregnancy, splenectomy, etc.).• The first-line treatment of uncomplicated P. falciparum malaria in adults is an artemisinin-derivative combination therapy (ACT): artemether-lumefantrine or artenimol-piperaquine. When such treatment is unavailable, not tolerated, or contraindicated, if interactions with concomitant medication are possible, or if ACT fails, then treatment with atovaquone-proguanil is an alternative option. Pregnant women (1st trimester) presenting with uncomplicated P. falciparum malaria should be hospitalized and treated with atovaquone-proguanil, or quinine if vomiting occurs. From the 2nd trimester on, priority should be given to artemether-lumefantrine or artenimol-piperaquine.• Uncomplicated malaria caused by species other than P. falciparum (i.e., P. vivax, P. ovale, P. malariae, or P. knowlesi) is treated with chloroquine or ACT. The latter is preferable in cases of co-infection or P. vivax malaria in travelers returning from a region known for resistance to chloroquine.• To prevent relapses in individuals infected with P. vivax or P. ovale, the dormant liver forms must be eliminated using primaquine, for which temporary use authorization (TUA) may be obtained once possible contraindications have been ruled out (glucose-6-phosphate dehydrogenase [G6PD] deficiency, pregnancy, breastfeeding).
- Published
- 2019
- Full Text
- View/download PDF
10. Tuberculous meningitis: Challenges in diagnosis and management
- Author
-
O. Bouchaud and F. Méchaï
- Subjects
medicine.medical_specialty ,Tuberculosis ,GeneXpert MTB/RIF ,business.industry ,Disease ,urologic and male genital diseases ,medicine.disease ,Tuberculous meningitis ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Neurology ,Tuberculosis, Meningeal ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Neurology (clinical) ,Intensive care medicine ,business ,Meningitis ,030217 neurology & neurosurgery ,Rifampicin ,medicine.drug - Abstract
Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis. In 2017, approximately 10 million people developed TB worldwide, of whom more than 100,000 new cases of TBM are estimated to occur per year. In patients who are co-infected with HIV-1, TBM has a mortality approaching 50%. Diagnosis of TBM is often delayed by the insensitive and lengthy culture technique required for disease confirmation. GeneXpert represents the most significant advance in TBM diagnostics over the past decade, but it lacks sensitivity and cannot be used to rule out the diagnosis. Higher volume of cerebrospinal fluid (CSF) seems to be interesting to improve the diagnosis performances. New rapid and accurate diagnostic tools are necessary. Better advances have been made concerning the anti-tuberculosis chemotherapy of TBM, with the publication of clinical trials and pharmacokinetic studies exploring the use of higher rifampicin doses and fluoroquinolones. The rise of drug-resistant TBM is another challenge for management because TBM caused by multidrug resistant organisms results in death or severe disability in almost all sufferers.
- Published
- 2019
11. Abcès intra-abdominaux : épidémiologie microbienne
- Author
-
F. Jaureguy, E. Zogheib, C. Tresallet, A. Le bian, A. Kolakowska, F. Méchaï, O. Ahmed, and H. Cordel
- Subjects
Infectious Diseases - Published
- 2021
- Full Text
- View/download PDF
12. Tuberculose pulmonaire : évolution radiologique des lésions broncho-pulmonaires en fin de traitement
- Author
-
C Fockyee, Diane Bouvry, F. Méchaï, Olivier Bouchaud, A. Raffetin, Michel Brauner, Pierre-Yves Brillet, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Laboratoire de Pédagogie de la Santé (LPS), and Université Sorbonne Paris Cité (USPC)-Université Sorbonne Paris Nord
- Subjects
Pulmonary and Respiratory Medicine ,Gynecology ,medicine.medical_specialty ,business.industry ,[SDV]Life Sciences [q-bio] ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Pulmonary tuberculosis ,Broncho-pulmonary ,Medicine ,030212 general & internal medicine ,business - Abstract
Resume Objectifs Decrire les lesions broncho-pulmonaires residuelles et evaluer l’interet de la tomodensitometrie (TDM) en fin de traitement d’une tuberculose pulmonaire. Materiels et methodes Analyse des TDM thoraciques initiales et de fin de traitement de 56 patients avec tuberculose pulmonaire selon une grille de lecture incluant les lesions parenchymateuses et des voies aeriennes. Les donnees TDM de fin de traitement ont ete analysees en fonction des donnees cliniques, mycobacteriologiques et du TDM initial. Resultats Des lesions actives (cavite a paroi epaisse et/ou micronodules centrolobulaires) persistaient chez 24 patients (43 %) apres un traitement moyen de 7 mois. La persistance de ces signes d’activite etait correlee initialement a la presence d’un syndrome cavitaire (p = 0,027), a une atteinte bronchique predominant en sous-segmentaire, a une extension plus importante des micronodules (p = 0,024) et a des bronchectasies (p = 0,04). Ces lesions residuelles n’etaient pas associees a un risque plus eleve de rechute. Conclusion La persistance de signes d’activite sur la TDM de fin de traitement d’une tuberculose ne correspond pas obligatoirement a une absence de guerison mais a un retard radiologique. Cette imagerie est neanmoins utile pour faire le bilan des sequelles de l’arbre bronchique, voire estimer le risque de complications ulterieures.
- Published
- 2019
- Full Text
- View/download PDF
13. Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis
- Author
-
F. Méchaï, O. Aoun, Benjamin Wyplosz, Olivier Bouchaud, J. Figoni, and Jérôme Robert
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Tuberculosis ,Isolation (health care) ,Antitubercular Agents ,fluids and secretions ,Intensive Phase ,Isolation precautions ,Surveys and Questionnaires ,Internal medicine ,Humans ,Medicine ,Practice Patterns, Physicians' ,business.industry ,Transmission (medicine) ,Sputum ,medicine.disease ,Regimen ,Infectious Diseases ,Health Care Surveys ,Practice Guidelines as Topic ,Drug Therapy, Combination ,France ,medicine.symptom ,business - Abstract
OBJECTIVES To evaluate isolation practices and management of sputum smear-positive tuberculosis (TB) in France. METHODS A survey was conducted using a questionnaire e-mailed in 2011 and 2012 to physicians of the French Society of Infectious Diseases, the French Respiratory Society and the French National Society of Internal Medicine. RESULTS Of 311 responders, a quarter stated they treated more than 25 TB cases per year. A total of 87.8% declared they routinely used a four-drug regimen in the initial intensive phase. Of the 311 physicians who responded, 31.9% removed isolation precautions after three negative acid-fast bacilli (AFB) sputum results, 19.0% after 15 days of treatment and 34.1% only in case of clinical improvement. According to 71% of the responders, discharge from hospital despite positive AFB sputum smear results was 'possible'. A routine AFB sputum smear was performed after 2 months of treatment by only 21% of the responders. CONCLUSION Despite recent national guidelines, the management of isolation precautions for sputum smear-positive TB remains heterogeneous, and a significant proportion of physicians use a three-drug regimen. Further efforts should be made to implement TB guidelines, mainly by raising awareness through national scientific institutions, but also by obtaining better evidence.
- Published
- 2015
- Full Text
- View/download PDF
14. [Pulmonary tuberculosis: Radiological evolution of broncho-pulmonary lesions at the end of treatment]
- Author
-
F, Méchaï, C, Fock-Yee, D, Bouvry, A, Raffetin, O, Bouchaud, M, Brauner, and P Y, Brillet
- Subjects
Adult ,Male ,Adolescent ,Bronchi ,Middle Aged ,Young Adult ,Treatment Outcome ,Humans ,Female ,France ,Tomography, X-Ray Computed ,Lung ,Tuberculosis, Pulmonary ,Aged ,Retrospective Studies - Abstract
To describe the residual broncho-pulmonary lesions and evaluate the role of CT scanning at the end of treatment of pulmonary tuberculosis.Analysis of the initial and end of treatment CT scans of 56 patients with pulmonary tuberculosis according to a reading grid including parenchymatous and airways lesions. The CT data at the end of treatment were analysed in relation to the clinical and microbiological data, and the original CT scan.Active lesions (thick walled cavities and/or centrilobular micronodules) persisted in 24 patients (43%) after a mean treatment period of 7 months. The persistence of these signs of activity was correlated with the initial presence of a cavitary syndrome (p=0.027), with predominant sub-segmentary bronchial involvement, with extensive micronodular spread (p=0.024) and with bronchiectasis (p=0.04). These residual lesions were not associated with an increased risk of relapse.The persistence of signs of activity on the CT scan at the end of treatment of tuberculosis do not necessarily correspond to an absence of cure but to a radiological delay. This imaging is nevertheless useful to make an assessment of any subsequent changes in the bronchial tree and to estimate the risk of later complications.
- Published
- 2017
15. Vascular graft infection due to Pasteurella multocida
- Author
-
J. Brossier, F. Fourreau, F. Méchaï, O. Bouchaud, and Bertrand Picard
- Subjects
Bacillus (shape) ,Pasteurella multocida ,Multidisciplinary ,Case Study ,biology ,business.industry ,animal diseases ,Gram Negative Bacillus ,fungi ,Vascular graft ,biology.organism_classification ,Graft infection ,surgical procedures, operative ,Vascular graft infection ,Immunology ,otorhinolaryngologic diseases ,Medicine ,business - Abstract
Background Vascular graft infections are infrequent complications with important morbidity and mortality rates. Pasteurella multocida, a Gram negative bacillus, is a normal oral commensal of many animals. For mankind, it is a pathogenous bacillus which is rarely implicated in vascular grafts. Case report We report hereafter the fourth case introduced in the international literature about vascular graft infections caused by P. multocida. The patient was successfully treated with a combination of a surgical graft change and a 6 weeks bi-antibiotic therapy. Discussion There is fours case reported in litterature with quite different antibiotic drugs and duration. Conclusion P. multicoda graft infection should be long with initial intravenous drug and mainteance traitement should not be required.
- Published
- 2015
- Full Text
- View/download PDF
16. Évaluation sur un an de l’efficience de notre laboratoire de microbiologie pour le diagnostic de la tuberculose
- Author
-
J.-R. Zahar, A. Barbat, S. Kabiche, F. Méchaï, Alexandre Bleibtreu, A. Jacolot, E. Carbonnelle, Typhaine Billard-Pomares, and P. Cruaud
- Subjects
Infectious Diseases - Abstract
Introduction Evaluer l’efficience du laboratoire pour le diagnostic bacteriologique de la tuberculose en croisant les cas cliniquement repertories a ceux bacteriologiquement documentes au cours de l’annee 2015. Materiels et methodes Interrogation des donnees patients a partir du logiciel d’aide a la prescription, du logiciel de production de resultats de laboratoire et du logiciel de gestion du dossier patient. Inclusion des patients repertories en 2015. Cent soixante-cinq cas repartis en 4 groupes selon la presence d’une prescription d’isoniazide (INH+ ou −) et les resultats d’investigations microbiologiques (BAC+ ou BAC−) : groupe A (INH+, BAC− [ n = 10]) ; groupe B (INH+, BAC+ et culture positive a Mycobacterium tuberculosis complex [Mtb cx] [C+] [ n = 71]) ; groupe C (INH+, BAC+ mais culture negative a Mtb cx [C−] [ n = 54]) et groupe D (INH−, BAC+, C+ [ n = 30]). Pour l’objectif poursuivi, seuls les groupes B, C et D ayant fait l’objet d’investigations bacteriologiques, ont ete retenus ( n = 155). Pour chaque patient, les donnees cliniques ont ete analysees. Resultats L’analyse des donnees cliniques a permis d’obtenir les resultats suivants. Pour les 71 patients du groupe B (45 %), il existait une parfaite coherence clinique, biologique et therapeutique avec 40 tuberculoses pulmonaires (TP) 13 tuberculoses mixtes (TM) et 18 tuberculoses extrapulmonaires (TXP). Pour les 54 patients du groupe C (35 %), 4 cas etaient inexploitables car sans information clinique. Sur les 50 cas restants, nous avons repertorie 10 infections tuberculeuses latentes (ITL), 6 mycobacterioses, 11 traitements d’epreuves, 8 TP, TM ou TXP deja sous traitement lors des investigations bacteriologiques pouvant expliquer les resultats de culture negatifs. En revanche, pour 15 cas (2 TP, 4 TM et 9 TXP) une C+ n’a pas ete obtenue. Pour les 30 patients du groupe D (19 %), nous avons repertorie 19 TP, 2 TM et 9 TXP. L’efficience globale de laboratoire etait de 96 % pour les TP, meilleure que pour les TM (79 %) et TEX (75 %). Une analyse du nombre des investigations pratiquees pour les C− indique qu’un nombre insuffisant d’investigations est a mettre en avant. Conclusion A partir de l’ensemble des cas de TB repertories, le laboratoire a apporte un diagnostic positif pour 96 % des cas de TP. Il apparait que l’efficience du laboratoire est satisfaisante pour le diagnostic des TP et la principale cause de deficit de diagnostic bacteriologique repose sur un defaut d’investigations. Pour les TXP, l’analyse est plus complexe ; neanmoins le laboratoire a apporte sa contribution au diagnostic dans 3 cas sur 4.
- Published
- 2017
- Full Text
- View/download PDF
17. Améliorer l’identification de nos cas de tuberculose : place d’une alerte à partir du logiciel informatisé de prescription de médicaments
- Author
-
E. Carbonnelle, Typhaine Billard-Pomares, F. Ruiz, F. Méchaï, Alexandre Bleibtreu, P. Cruaud, A. Jacolot, S. Kabiche, and J.-R. Zahar
- Subjects
Infectious Diseases - Abstract
Introduction Identifier rapidement les cas de tuberculose en milieu hospitalier est un objectif prioritaire pour prevenir les cas secondaires chez les patients et les soignants. Multiplier les sources d’informations permettant une alerte rapide est primordiale. Nous avons evalue sur une periode d’un an la place du logiciel d’aide a la prescription medicamenteuse dans la detection des patients suivis pour tuberculose pulmonaire au sein d’un groupe hospitalier universitaire confronte a une des incidences de tuberculose pulmonaire les plus elevees de France. Materiels et methodes Tous les cas de tuberculose ont ete repertories du 01/01/2015 au 31/12/2015 en utilisant le logiciel d’aide a la prescription medicamenteuse et le logiciel de gestion de resultats de laboratoire. Toutes les prescriptions incluant de l’isoniazide (INH) en complement des donnees du laboratoire de microbiologie ont ete prises en compte. Resultats Pendant la periode d’etude, 165 cas ont ete identifies. Parmi ceux-ci, 30 (18 %) patients l’etaient uniquement par culture positive (absence de prescription informatisee d’INH). Cent trente-cinq patients (82 %) avaient une prescription d’INH dont 71 (52 %) avec une culture positive a Mycobacterium tuberculosis complex , 10 (8 %) sans aucune investigation bacteriologique (8 diagnostics faits l’annee precedente et 2 infections tuberculeuses latentes [ITL]) et 54 (40 %) sans aucun prelevement positif malgre des investigations bacteriologiques. Il s’agissait pour ce groupe de 10 ITL, 6 mycobacterioses (MA) et 38 cas cliniquement suspects de tuberculose maladie. En excluant les ITL, les MA et les cas diagnostiques l’annee precedente, 38 (28 %) des 135 cas retenus l’etaient grâce au logiciel d’aide a la prescription des medicaments. Conclusion En pratique le logiciel d’aide a la prescription a permis dans notre travail d’identifier 38 cas supplementaires de tuberculose maladie soit 23 % des cas de l’annee etudiee. L’alerte a partir du logiciel d’aide a la prescription nous parait etre un complement a ne pas negliger en complement de l’alerte microbiologique afin d’elargir la population des cas autour desquels une enquete doit etre menee dont la recherche de cas secondaires eventuels afin de maitriser au mieux le risque de diffusion intra-hospitalier.
- Published
- 2017
- Full Text
- View/download PDF
18. MYCOBACT-01 - Comment améliorer le diagnostic microbiologique des tuberculoses pulmonaires ?
- Author
-
T. Billard Pomares, H. Cordel, E. Carbonnelle, P. Cruaud, Olivier Bouchaud, and F. Méchaï
- Subjects
Infectious Diseases - Published
- 2016
- Full Text
- View/download PDF
19. Primary Mycobacterium bovis infection revealed by erythema nodosum
- Author
-
F, Méchaï, C, Soler, O, Aoun, M, Fabre, A, Mérens, P, Imbert, and C, Rapp
- Subjects
Young Adult ,Erythema Nodosum ,Milk ,Treatment Outcome ,Zoonoses ,Antitubercular Agents ,Animals ,Humans ,Tuberculosis ,Cattle ,Female ,Mycobacterium bovis ,Tuberculosis, Bovine - Abstract
Mycobacterium bovis is responsible for a zoonosis originating in cattle. This disease has rarely affected man in industrialised countries since the establishment of veterinary surveillance in cattle. We report the case of a young female patient who developed a Mycobacterium bovis primary infection revealed by erythema nodosum. Infection was probably due to the consumption of non-pasteurised milk in Morocco. This clinical manifestation is rare and physicians ought to be aware of this imported pathology.
- Published
- 2011
20. [Giant retroperitoneal hydatid cyst in a traveller]
- Author
-
A, Cambon, P, Imbert, V, Duverger, G, Dumas, M, Danguy des Déserts, A, Crémades, F, Méchaï, F, Simon, and C, Rapp
- Subjects
Travel ,Echinococcosis ,Humans ,Female ,Retroperitoneal Space ,Aged - Abstract
Giant hydatid cyst located in the retroperitoneal space is rare. The purpose of this report is to present a case cured by surgery in an adult traveller.In August 2009, a 67-year-old female who traveled frequently to Lebanon was admitted for assessment of a giant retroperitoneal hydatid cyst discovered coincidentally following palpation of an abdominal mass in 1997. From 1966 to 1975, the patient had undergone several surgical procedures for pulmonary and hepatic hydatidosis, complicated by vomica and anaphylactic shock. In 1997, computed tomography showed that the retroperitoneal cyst measured 100 mm at the widest point. At that time, the patient refused to undergo further surgery and was treated medically using albendazole initially in association with praziquantel. In 2009, the cyst had expanded to 180 mm at the widest point and the patient finally consented to perikystectomy. Excision was total and recovery was uneventful. Histology examination confirmed the viability of the cyst. Follow-up examination at 12 months indicated no relapse.The retroperitoneal space is a rare location for hydatidosis. Occurrence in this location is generally primary. In case of discovery of a liquid-filled retroperitoneal mass, a history of travel to an endemic area for hydatid disease should be elicited. Diagnosis relies on radiological findings and positive serology. Since retroperitoneal cysts are often giant, they respond poorly to medical treatment. Similarly radiological treatment is difficult due to retroperitoneal location. Surgery, preferably perikystectomy, is the treatment of choice.
- Published
- 2011
21. [Duodenal ulcers caused by chloroquine-proguanil association]
- Author
-
X, Roux, P, Imbert, F, Rivière, F, Méchaï, and C, Rapp
- Subjects
Adult ,Male ,Antimalarials ,Drug Combinations ,Travel ,Proguanil ,Duodenal Ulcer ,Humans ,Chloroquine ,Chemoprevention ,Malaria - Abstract
Chloroquine-proguanil association is recommended for prophylaxis against falciparum malaria in countries with a low prevalence of chloroquine resistance. It is usually well tolerated with mild side effects consisting mainly of transient digestive discomfort and buccal manifestations (mouth sores or ulcers). The purpose of this report is to describe a case of duodenal ulcers presenting as epigastric pain with 10-kg weight-loss in a 32-year-old man taking chloroquine-proguanil for malaria prophylaxis during a stay in Haiti. No other causes of duodenal ulcers or weight-loss were found. Chloroquine-proguanil prophylaxis was discontinued and replaced by omeprazole for four weeks. Symptoms improved quickly and full recovery was observed within one month. To our knowledge, the occurrence of duodenal ulcers under chloroquine-proguanil association is quite rare, but possibly severe. Upper digestive endoscopy should be performed if a patient under chloroquine-proguanil develops abdominal pain especially in association with weight-loss. If endoscopy reveals duodenal ulcers, chloroquine-proguanil should be discontinued and replaced by another prophylactic regimen.
- Published
- 2011
22. [Management of candidemia and invasive candidiasis]
- Author
-
F, Taieb, F, Méchaï, A, Lefort, F, Lanternier, M-E, Bougnoux, and O, Lortholary
- Subjects
Decision Trees ,Candidiasis ,Candidemia ,Humans - Abstract
Candida species is the fourth most common cause of bloodstream infection and is the leading cause of invasive fungal infection among hospitalized patients. Acute disseminated candidiasis remains a life-threatening disease that now occurs mainly in intensive care units hospitalized patients. Delay in treatment of Candida bloodstream infections could be minimized by the development of more rapid and sensitive diagnostic techniques for the identification of Candida bloodstream infections. Current guidelines for the management of invasive candidiasis recommend fluconazole or an echinocandin as the primary therapeutic option. The optimal choice of the antifungal agent should depend on local epidemiology, prior antifungal therapy and patient's characteristics.
- Published
- 2010
23. [Epidemiological and clinical features of enteroviral meningitis: a case series of 59 adult patients]
- Author
-
F, Méchaï, F, Rivière, X, Roux, A, Mérens, C, Bigaillona, C, Ficko, P, Imbert, and C, Rapp
- Subjects
Adult ,Male ,Young Adult ,Adolescent ,Enterovirus Infections ,Humans ,Female ,Middle Aged ,Meningitis, Viral ,Retrospective Studies - Abstract
To describe the epidemiological and clinical features of enteroviral meningitis as well as the biological profile of the cerebrospinal fluid (CSF).A retrospective study conducted in a single centre between 2004 and 2008. All aseptic meningitis due to Enterovirus were included.Fifty-nine patients were included. The triad including fever, headache and neck stiffness was reported in 62% of patients. Twelve patients (20%) had a neutrophilic leukocytosis and 23 (39%) an elevated CRP level. Twenty-eight patients (47%) had a prominent neutrophilic reaction in the CSF and nine (15.2%) had a low glucose concentration. A presumptive anti-bacterial treatment was initiated in 47 patients (80%) for an average of 3.2 days.Due to the lack of specificity of clinical features and biological manifestations of Enterovirus meningitis, the widespread use of real-time Enterovirus PCR is a priority for reducing the number of unnecessary anti-bacterial treatment. Guidelines based on clinical and biological features may be associated to help physicians in the differential diagnosis between bacterial and viral meningitides.
- Published
- 2009
24. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
- Author
-
Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, Jérémy Jaffré, Hugo Langris, Valérie Pourcher, Frédéric Schramm, Nadine Lemaître, Jérôme Robert, O. Bouchaud, T. Billard-Pomares, E. Carbonnelle, F. Mechaï, H. Nunes, M. Pellan, A.-S. Morin, C. Dumesnil, J. Dumoulin, A.-L. Roux, M. Jachym, D. le Du, D. Marigot-Outtandy, S. Abgrall, V. Chambrin, C. Guillet, B. Fantin, A. Galy, J.-W. Decousser, J.D. Lelièvre, S. Gallien, B. Nebbad-Lechani, L. Deconinck, S. Bulifon, N. Fortineau, B. Wyplosz, F. Cohen, N. Lemaitre, B. Crestani, N. Grall, C. Pierre-Audigier, C. Rioux, Y. Yazdanpanah, C. Le Jeunne, P. Morand, N. Roche, J. Pavie, P. Loulergue, V. Delcey, E. Lecorché, A.-L. Munier, F. Mougari, P. Sellier, E. Bille, A. Ferroni, R. Guéry, A. Hummel, J. Lourenco, A. Aubry, I. Bonnet, E. Caumes, C. Londner, F. Morel, K. Lacombe, V. Lalande, J.-L. Meynard, N. Veziris, N. De Castro, B. Denis, M. Lafaurie, J.-M. Molina, A. Canestri, L. Lassel, G. Pialoux, C. Verdet, A.-L. Nardi, M. Gominet, and E. Catherinot
- Subjects
Tuberculosis ,Isoniazid ,Drug resistance ,Risk factors ,Epidemiology ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.
- Published
- 2021
- Full Text
- View/download PDF
25. Mycoplasma hominis osteitis in an immunocompetent man
- Author
-
M. Freslon, Christophe Burucoa, G. Le Moal, F. Méchaï, Cendrine Godet, and S. Duchêne
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,Antibiotics ,Mycoplasmataceae ,Mycoplasma hominis ,Biology ,chemistry.chemical_compound ,Medical microbiology ,medicine ,Humans ,Mycoplasma Infections ,Osteitis ,Antibacterial agent ,Tibia ,Clindamycin ,General Medicine ,medicine.disease ,biology.organism_classification ,Dermatology ,Infectious Diseases ,chemistry ,Immunology ,Linezolid ,Immunocompetence ,medicine.drug - Abstract
Mycoplasma hominis has been associated with pelvic inflammatory illness, postpartum and neonatal infections and respiratory tract diseases. It is rarely isolated from patients with other infections. Reported here is a case of tibial osteitis that occurred in a 16-year-old immunocompetent man. Clinical and laboratory findings improved under treatment with clindamycin and fluoroquinolones.
- Published
- 2006
26. U-13: Évaluation de la qualité des pratiques de perfusion veineuse périphérique dans un service de maladies infectieuses et tropicales
- Author
-
Nicolas Vignier, M. Teti, M. Gousseff, Olivier Bouchaud, M. Tatay, and F. Méchaï
- Subjects
Infectious Diseases - Abstract
Introduction – objectifs Evaluer la conformite aux recommandations de bonnes pratiques de la gestion des catheters veineux peripheriques en hospitalisation de maladies infectieuses. Materiels et methodes Etude observationnelle prospective dans le secteur d’hospitalisation classique de 22 lits de maladies infectieuses du CHU Avicenne. Recueil hebdomadaire pendant 2 mois de donnees cliniques relatives a la perfusion peripherique de tous les malades hospitalises : justification et duree de maintien de la voie d’abord, nombre et type de complications associees. Resultats Sur 2 mois, 174 patients hospitalises ont ete evalues et 96 (55,2 %) avaient une perfusion peripherique. Six (6,25 %) de ces perfusions n’etaient pas justifiees, dont 2 etaient associees a une complication mineure malgre une duree de perfusion correcte La date de pose du catheter n’etait notee par les infirmieres que dans 43 % des cas, dont 1 seul cas avec maintien > 96 heures (5 jours), sans complication associee. Conclusion Les recommandations de bonne pratique concernant l’indication, le maintien et la prevention des complications des perfusions peripheriques etaient plutot bien respectees dans notre service, en dehors de la tracabilite de la date de pose de la perfusion. Les complications observees n’etaient pas liees a une duree de maintien excessive.
- Published
- 2014
- Full Text
- View/download PDF
27. K-03: Tuberculose pulmonaire bacillifère : intérêt de l’amikacine en début de traitement ?
- Author
-
Nicolas Vignier, M. Tatay, F. Méchaï, Olivier Bouchaud, and M. Gousseff
- Subjects
Infectious Diseases - Abstract
Introduction – objectifs Evaluer le benefice de l’amikacine (AmK) en debut de traitement d’une tuberculose bacillifere (TTB) sur le delai de negativation de l’examen des crachats. Materiel et methodes Etude pilote prospective non randomisee monocentrique au CHU d’Avicenne sur la periode 2010-2013. Evaluation comparative sequentielle du delai de negativation de l’examen microscopique (EM) et de la culture des crachats/tubages entre TTB classique (TTBc) et TTB associe a AmK (TTB-AmK) IV 15 mg/kg/j pendant 7 jours adapte aux dosages. Les patients avec souche resistante, infection VIH ou insuffisance renale etaient exclus. Resultats L’etude a porte sur 45 patients : 30 (66,6 %) dans le groupe TTBc, 15 (33,3 %) dans le groupe TTB-AmK. Le sex ratio H/F etait de 4,6. La toux et les expectorations etaient retrouvees chez respectivement 41 (91,1 %) et 32 (71,1 %) des patients. Une majorite des patients (42 soit 93,3 %) avaient une caverne pulmonaire. Les medianes du delai de negativation de l’EM etaient respectivement de 26,5 [14-56] et 48 [19,5-69,5] jours dans les groupes TTBc et TTB-Amk avec une difference non significative (p = 0,52). Le delai de negativation de la culture n’etait connu que pour 26 patients (57,7 %) : 42,2 jours [14-90] en moyenne pour les 18 patients du groupe TTBc et 63,2 jours [14-77] pour les 8 patients du groupe TTB-AmK. Les 19 (42,2 %) autres patients avaient une culture encore positive au premier EM negatif. Aucun effet secondaire lie a l’AmK n’a ete rapporte. Conclusion La tuberculose pulmonaire bacillifere necessite un isolement prolonge couteux et contraignant pour le patient. L’ajout d’AmK au TTB initial ne semble pas avoir d’impact sur le delai de negativation de l’examen microscopique, critere de non-contagiosite le plus souvent retenu. Une etude randomisee avec des effectifs plus importants serait necessaire pour confirmer ces resultats.
- Published
- 2014
- Full Text
- View/download PDF
28. K-01: Tuberculose pulmonaire : intérêt du scanner de fin de traitement
- Author
-
C Fockyee, D Bouvry, F. Méchaï, M. Brauner, Olivier Bouchaud, and P.-Y. Brillet
- Subjects
Infectious Diseases - Abstract
Introduction – objectifs Evaluer l’apport d’un scanner thoracique en fin de traitement antituberculeux. Etudier les facteurs predictifs de persistance de signes d’activite (cavites a parois epaisses +/- nodules centrolobulaires) et de lesions sequellaires bronchiques en fin de traitement. Materiels et methodes Etude comparative retrospective au CHU Avicenne d’octobre 2006 a mars 2012 par trois radiologues des scanners thoraciques pour tuberculose pulmonaire realises au debut et a la fin du traitement. Resultats L’etude a porte sur 56 patients dont 43 (77 %) hommes. Six patients etaient VIH+ (11 %). La persistance de signes d’activite radiologique residuelle (ARR) en fin de traitement etait retrouvee chez 24 patients asymptomatiques sur 56 (43 %) et etait associee significativement a la presence initiale de cavites (p = 0,03), de micronodules (p = 0,022) et d’une atteinte bronchique sous segmentaire. Les symptomes cliniques et l’immunodepression n’etaient pas associes significativement a une ARR. Des sequelles bronchiques, retrouvees chez 36 patients sur 56 (64 %), avaient pour facteurs predictifs initiaux les cavites (p = 0,003), les condensations (p = 0,004), les micronodules (p = 0,03) et une atteinte bronchique initiale a type de DDB (p Conclusion La presence isolee de signes d’ARR en fin de traitement temoigne probablement le plus souvent d’un retard radioclinique et ne doit pas faire prolonger le traitement par le clinicien. Le scanner thoracique peut neanmoins servir d’imagerie de reference en situation de rechute tuberculeuse, d’hemoptysie, de surinfection bacterienne ou de greffe aspergillaire.
- Published
- 2014
- Full Text
- View/download PDF
29. OA-WS-29 Imagerie des mycoses invasives osseuses
- Author
-
F. Méchaï, D. Zeitoun-Eiss, Sylvain Poirée, O. Lortholary, and O. Hélénon
- Subjects
Radiological and Ultrasound Technology ,Radiology, Nuclear Medicine and imaging - Abstract
Objectifs Decrire l’aspect en imagerie de l’atteinte osseuse dans le cadre de mycoses invasives. Materiels et methodes Analyse retrospective en radiographie standard, scanner et IRM de 6 cas de mycoses invasives chez des patients, pour la majorite immunodeprimes, avec atteinte osseuse. Le diagnostic a ete confirme dans ces 6 cas par des prelevements avec etude anatomo-pathologique ou mycologique. Resultats Nous illustrons differentes atteintes osseuses fongiques interessant les parois des sinus de la face, le rachis, la scapula et les os longs dont le point de depart est pulmonaire, cardiaque, cutane ou sinusal. Le mode d’extension se fait par contiguite ou par voie hematogene. Les lesions des sinus sont lytiques avec extension aux structures adjacentes (sinus caverneux, carotides, meninges et parenchyme cerebral). L’extension au rachis se caracterise par une osteite focale ou etagee ou par une spondylodiscite. Enfin l’atteinte des os longs se manifeste par des images d’osteolyse multifocales avec importante extension musculo-aponevrotique. Conclusion L’extension vertebrale ou aux os longs de la mycose invasive est moins connue et doit etre evoquee chez un patient immunodeprime presentant une atteinte viscerale. Le diagnostic radiologique reste cependant aspecifique et doit etre confirme par une biopsie.
- Published
- 2008
- Full Text
- View/download PDF
30. Staphylococcus aureus CC30 Lineage and Absence of sed,j,r-Harboring Plasmid Predict Embolism in Infective Endocarditis
- Author
-
Jean-Philippe Rasigade, Amélie Leclère, François Alla, Adrien Tessier, Michèle Bes, Catherine Lechiche, Véronique Vernet-Garnier, Cédric Laouénan, François Vandenesch, Catherine Leport, The AEPEI Study Group, B. Hoen, X. Duval, F. Alla, A. Bouvet, S. Briancxon, E. Cambau, M. Celard, C. Chirouze, N. Danchin, T. Doco-Lecompte, F. Delahaye, J. Etienne, B. Iung, V. Le Moing, J. F. Obadia, C. Leport, C. Poyart, M. Revest, C. Selton-Suty, C. Strady, P. Tattevin, F. Vandenesch, Y. Bernard, S. Chocron, P. Plesiat, I. Abouliatim, C. De Place, P. Y. Donnio, J. P. Carteaux, C. Lion, N. Aissa, B. Baehrel, R. Jaussaud, P. Nazeyrollas, V. Vernet, P. Nataf, C. Chidiac, H. Aumaître, J. M. Frappier, E. Oziol, A. Sotto, C. Sportouch, M. Bes, P. Abassade, E. Abrial, C. Acar, J. F. Alexandra, N. Amireche, D. Amrein, P. Andre, M. Appriou, M. A. Arnould, P. Assayag, A. Atoui, F. Aziza, N. Baille, N. Bajolle, P. Battistella, S. Baumard, A. Ben Ali, J. Bertrand, S. Bialek, M. Bois Grosse, M. Boixados, F. Borlot, A. Bouchachi, O. Bouche, S. Bouchemal, J. L. Bourdon, L. Brasme, F. Bricaire, E. Brochet, F. J. Bruntz, A. Cady, J. Cailhol, M. P. Caplan, B. Carette, O. Cartry, C. Cazorla, H. Chamagne, H. Champagne, G. Chanques, J. Chastre, B. Chevalier, F. Chometon, C. Christophe, A. Cohen, N. Colin de Verdiere, V. Daneluzzi, L. David, P. De Lentdecker, V. Delcey, P. Deleuze, E. Donal, B. Deroure, V. Descotes-Genon, K. Didier Petit, A. Dinh, V. Doat, F. Duchene, F. Duhoux, M. Dupont, S. Ederhy, O. Epaulard, M. Evest, J. F. Faucher, B. Fantin, E. Fauveau, T. Ferry, M. Fillod, T. Floch, T. Fraisse, J. M. Frapier, L. Freysz, B. Fumery, B. Gachot, S. Gallien, I. Gandjbach, P. Garcon, A. Gaubert, J. L. Genoud, S. Ghiglione, C. Godreuil, A. Grentzinger, L. Groben, D. Gherissi, P. Gue'ret, A. Hagege, N. Hammoudi, F. Heliot, P. Henry, S. Herson, P. Houriez, L. Hustache-Mathieu, O. Huttin, S. Imbert, S. Jaureguiberry, M. Kaaki, A. Konate, J. M. Kuhn, S. Kural Menasche, A. Lafitte, B. Lafon, F. Lanternier, V. Le Chenault, C. Lechiche, S. Lefèvre-Thibaut, A. Lefort, A. Leguerrier, J. Lemoine, L. Lepage, C. Lepouse', J. Leroy, P. Lesprit, L. Letranchant, D. Loisance, G. Loncar, C. Lorentz, P. Mabo, I. Magnin-Poull, T. May, A. Makinson, H. Man, M. Mansouri, O. Marcxon, J. P. Maroni, V. Masse, F. Maurier, M. C. Meyohas, P. L. Michel, C. Michelet, F. Mechaï, O. Merceron, D. Messika-Zeitoun, Z. Metref, V. Meyssonnier, C. Mezher, S. Micheli, M. Monsigny, S. Mouly, B. Mourvillier, O. Nallet, V. Noel, T. Papo, B. Payet, A. Pelletier, P. Perez, J. S. Petit, F. Philippart, E. Piet, C. Plainvert, B. Popovic, J. M. Porte, P. Pradier, R. Ramadan, J. Richemond, M. Rodermann, M. Roncato, I. Roigt, O. Ruyer, M. Saada, J. Schwartz, M. Simon, B. Simorre, S. Skalli, F. Spatz, J. Sudrial, L. Tartiere, A. Terrier De La Chaise, M. C. Thiercelin, D. Thomas, M. Thomas, L. Toko, F. Tournoux, A. Tristan, J. L. Trouillet, L. Tual, A. Vahanian, F. Verdier, V. Vernet Garnier, V. Vidal, P. Weyne, M. Wolff, A. Wynckel, N. Zannad, and P. Y. Zinzius
- Subjects
S. aureus ,MRSA ,infective endocarditis ,stroke ,CC30 ,enterotoxin ,Microbiology ,QR1-502 - Abstract
Staphylococcus aureus induces severe infective endocarditis (IE) where embolic complications are a major cause of death. Risk factors for embolism have been reported such as a younger age or larger IE vegetations, while methicillin resistance conferred by the mecA gene appeared as a protective factor. It is unclear, however, whether embolism is influenced by other S. aureus characteristics such as clonal complex (CC) or virulence pattern. We examined clinical and microbiological predictors of embolism in a prospective multicentric cohort of 98 French patients with monomicrobial S. aureus IE. The genomic contents of causative isolates were characterized using DNA array. To preserve statistical power, genotypic predictors were restricted to CC, secreted virulence factors and virulence regulators. Multivariate regularized logistic regression identified three independent predictors of embolism. Patients at higher risk were younger than the cohort median age of 62.5 y (adjusted odds ratio [OR] 0.14; 95% confidence interval [CI] 0.05–0.36). S. aureus characteristics predicting embolism were a CC30 genetic background (adjusted OR 9.734; 95% CI 1.53–192.8) and the absence of pIB485-like plasmid-borne enterotoxin-encoding genes sed, sej, and ser (sedjr; adjusted OR 0.07; 95% CI 0.004–0.457). CC30 S. aureus has been repeatedly reported to exhibit enhanced fitness in bloodstream infections, which might impact its ability to cause embolism. sedjr-encoded enterotoxins, whose superantigenic activity is unlikely to protect against embolism, possibly acted as a proxy to others genes of the pIB485-like plasmid found in genetically unrelated isolates from mostly embolism-free patients. mecA did not independently predict embolism but was strongly associated with sedjr. This mecA-sedjr association might have driven previous reports of a negative association of mecA and embolism. Collectively, our results suggest that the influence of S. aureus genotypic features on the risk of embolism may be stronger than previously suspected and independent of clinical risk factors.
- Published
- 2018
- Full Text
- View/download PDF
31. From Bed to Bench: Pre-analytical Stability of 29 Anti-infective Agents in Plasma and Whole Blood to Improve Accuracy of Therapeutic Drug Monitoring.
- Author
-
Magreault S, Pierredon D, Akinotcho-Relouzat J, Méchaï F, Lamy B, Jaureguy F, and Jullien V
- Abstract
Background: Therapeutic drug monitoring requires a validated assay and appropriate conditions for sample shipment and storage based on the stability of the compound to be analyzed. This study evaluated the stability of 29 antimicrobial compounds in whole blood (WB) and plasma samples under various storage conditions., Methods: The pre-analytical stability of 22 antibiotics (amoxicillin, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftobiprole, ceftolozane, ceftriaxone, ciprofloxacin, clindamycin, cloxacillin, daptomycin, levofloxacin, linezolid, meropenem, metronidazole, moxifloxacin, piperacillin, sulfamethoxazole, and trimethoprim), 2 beta-lactamase inhibitors (avibactam, tazobactam), and 5 antituberculosis drugs (ethambutol, isoniazid, pyrazinamide, rifabutin, and rifampicin) was assessed by WB for up to 24 hours at room temperature (RT) and 72 hours at +4°C. The stability in plasma was evaluated for up to 6 hours at RT, 24 hours at +4°C, 1 month at -20°C, and 6 months at -80°C., Results: Concerning WB stability, all investigated compounds were stable for 24 hours at RT, except meropenem and isoniazid, which were stable for 6 hours; however, for 24 hours at +4°C, all the compounds were stable. For storage durations of 48 and 72 hours at +4°C, all compounds were stable, except for ciprofloxacin, cotrimoxazole, and isoniazid. Concerning stability in plasma, all compounds were stable for 6 hours at RT, and all except isoniazid were stable for 24 hours at +4°C. All the tested compounds were stable for 7 days at -20°C, except isoniazid, for which a degradation of approximately 20% was observed. An important degradation was observed for beta-lactam antibiotics after 1 month at -20°C. All compounds were stable at -80°C for 6 months., Conclusions: The pre-analytical stabilities of several anti-infective compounds was described. The present results can be used to determine the appropriate conditions for shipping and storing samples dedicated to therapeutic drug monitoring of the investigated compounds., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. BedBiopsy: Diagnostic performance of bedside ultrasound-guided bone biopsies for the management of diabetic foot infection.
- Author
-
Hassold N, Bihan H, Moumba YP, Poilane I, Méchaï F, Assad N, Labbe-Gentils V, Sal M, Koutcha ON, Martin A, Radu D, Martinod E, Cordel H, Vignier N, Tatulashvili S, Berkane N, Carbonnelle E, Bouchaud O, and Cosson E
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Osteitis, Ultrasonography, Interventional methods, Bone and Bones pathology, Bone and Bones diagnostic imaging, Diabetic Foot diagnostic imaging, Image-Guided Biopsy methods
- Abstract
Objective: We aimed to assess the feasibility and diagnostic performance of ultrasound-guided bone biopsies at the bedside of diabetic patients admitted for suspected foot osteitis not requiring surgery., Research Design and Methods: In this retrospective monocentric study, we compared the performance of ultrasound-guided (n = 29 consecutive patients, Dec.2020-Oct.2022) versus surgical (n = 24 consecutive patients, Jan.2018-Nov.2020) bone biopsies at confirming or ruling out diabetic foot osteitis (primary outcome)., Results: Patient characteristics were similar in the two intervention groups, including arteritis prevalence (62.3 %), SINBAD score, and wound location (phalanges 36 %, metatarsus 43 %, and calcaneus 21 %). However, the ultrasound-guided group was older (67 ± 11 versus 60 ± 13 years respectively, P = 0.047) and had more type 2 diabetes (97 % versus 75 %, P = 0.038). Diagnostic performance (i.e., capacity to confirm or rule out suspected osteitis) was similar for ultrasound-guided (28/29 cases: 25 confirmations, 3 invalidations) and surgical (24 confirmations/24) biopsies, P = 0.358. No biopsy-related side effect or complication was observed for either intervention, even for patients on antiaggregation and/or anticoagulation therapy. The mean (± standard deviation) time necessary to perform the biopsy was shorter in the ultrasound-guided group (2.6 ± 3.0 versus 7.2 ± 5.8 days, respectively, P < 0.001) and wound evolution at three months was more favorable (83.3 versus 41.2 %, P = 0.005) (94.4 % versus 66.7 %, respectively, patients with new surgical procedure within six months excluded; P = 0.055). Even though not statistically significant, healing rates in terms of wound and osteitis at six months were also better in the ultrasound-guided group (wound: 40.9 % versus 36.8 %; P = 0.790, and osteitis: 81.8 vs 55.6 % P = 0.071)., Conclusion: In diabetic patients with suspected foot osteitis not requiring surgery, bedside ultrasound-guided bone biopsies may constitute a promising alternative to surgical biopsies. This intervention provided excellent tolerance and microbiological documentation, short lead-times, and more favorable wound prognosis., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Automated HPLC-MS/MS assay for the simultaneous determination of ten plasma antibiotic concentrations.
- Author
-
Magréault S, Jaureguy F, Zahar JR, Méchaï F, Toinon D, Cohen Y, Carbonnelle E, and Jullien V
- Subjects
- Humans, Chromatography, High Pressure Liquid methods, Chromatography, Liquid methods, Aztreonam, Drug Monitoring methods, Reproducibility of Results, Anti-Bacterial Agents, Tandem Mass Spectrometry methods
- Abstract
Therapeutic drug monitoring (TDM) of antibiotics (ATB) in patients with serious bacterial infections allows optimization of the efficacy of the treatment while reducing the risk of toxicity. Notably, early measurement of plasma beta-lactam concentration has been shown to be associated with reduced mortality in intensive care patients. In this context, a rapid, robust, and accurate assay method is essential for daily TDM. A fully automated procedure for quantification of the plasma concentrations of ten ATB was developed. The ATB were divided into two calibration pools, with Pool 1: aztreonam, ceftobiprole, cefoxitin, avibactam, tazobactam and Pool 2: metronidazole, ceftriaxone, daptomycin, ceftolozane, moxifloxacin. Sample preparation consisting of acetonitrile plasma protein precipitation and H20 dilution was applied to all analytes. This procedure was carried out by an automated sample preparation system directly coupled to a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. Since the instrument extracts sample n while sample n-1 is in the LC-MS/MS system, the delay between obtaining the results for two samples corresponds to the analytical run time, which is less than 7 min. The method was validated according to the Food and Drug Administration guidelines. The method was sensitive (lower limit of quantification 0.1-1 mg/L, depending on the ATB), accurate (intra/inter-assay bias -14.8 to 14.2 %) and precise (intra/inter-assay CVs 1.27 to 16.3 %). Application of the TDM assay was illustrated by the report of an intensive care patient treated with the ceftazidime/aztreonam/avibactam combination. Four assays were performed in 8 days with results returned within 24 h to quickly manage the dose regimen in this patient. An automated, simple, rapid, robust LC-MS/MS analysis was developed and validated for the simultaneous quantification of plasma concentrations of 10 ATB and was applied with success to perform TDM. This method provides a shorter turnaround time than classic sample batch-based analytical methods., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
- Author
-
Kherabi Y, Fréchet-Jachym M, Rioux C, Yazdanpanah Y, Méchaï F, Pourcher V, Robert J, and Guglielmetti L
- Subjects
- Antitubercular Agents therapeutic use, Fluoroquinolones therapeutic use, France epidemiology, Humans, Retrospective Studies, Treatment Outcome, Extensively Drug-Resistant Tuberculosis drug therapy, Extensively Drug-Resistant Tuberculosis epidemiology, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant epidemiology
- Abstract
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
- Published
- 2022
- Full Text
- View/download PDF
35. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
- Author
-
Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Méchaï F, Joly V, Yazdanpanah Y, and Molina JM
- Subjects
- Alkynes, Benzoxazines adverse effects, Cyclopropanes, Heterocyclic Compounds, 3-Ring, Humans, Oxazines therapeutic use, Piperazines, Pyridones, Raltegravir Potassium adverse effects, Retrospective Studies, Treatment Outcome, Viral Load, Anti-HIV Agents adverse effects, Coinfection drug therapy, HIV Infections complications, HIV Infections drug therapy, HIV-1 genetics, Tuberculosis complications, Tuberculosis drug therapy
- Abstract
Background: There are limited data comparing the efficacy and safety of raltegravir and dolutegravir to that of efavirenz in HIV-1/tuberculosis (TB) coinfected patients., Methods: We conducted a 10-year retrospective study in 4 centers in France. We included all HIV-1/tuberculosis coinfected patients starting antiretroviral therapy with a rifampicin-based regimen, with a plasma HIV RNA level (VL) > 1000 copies/mL. The primary endpoint was the proportion of patients with virological success that is, with VL <50 copies/mL at W48 using an Intention-To-Treat analysis, using last-observation-carried-forward to impute missing data. We also assessed antiretroviral therapy safety, analyzing treatment discontinuation for adverse events., Results: Between 2010 and 2020, 117 patients were included. Thirty-nine (33.3%) were treated with raltegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs), 19 (16.2%) with dolutegravir (and 2 NRTIs) and 59 (50.4%) with efavirenz (and 2 NRTIs). At W48, the primary endpoint was achieved in 24 patients (61.5%) in the raltegravir group, in 12 (63.2%) in the dolutegravir group, and in 41 (69.5%) in the efavirenz group using an Intention-To-Treat analysis ( P = 0.68). Emergence of drug resistance in patients with virological failure, defined as a VL >50 copies/mL, was observed in 3 patients with efavirenz and one patient with raltegravir. Rate of treatment discontinuation for drug-related adverse events was 10.3%, 10.6%, 16.9% for raltegravir, dolutegravir and efavirenz respectively ( P = 0.67)., Conclusions: In this retrospective cohort study, raltegravir and dolutegravir yielded similar efficacy and safety results to efavirenz for the treatment of HIV-1/TB coinfected patients., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
36. Use of Whole-Genome Sequencing to Explore Mycobacterium tuberculosis Complex Circulating in a Hotspot Department in France.
- Author
-
Billard-Pomares T, Marin J, Quagliaro P, Méchaï F, Walewski V, Dziri S, and Carbonnelle E
- Abstract
The Seine-Saint-Denis is the French metropolitan department with the highest incidence of tuberculosis (TB). Our aim was to explore epidemiological and phylogenetic characteristics of TB strains in this hotspot department. We performed WGS on 227 strains of Mycobacterium tuberculosis complex isolated from patients at the Avicenne Hospital from 2016 to 2021 and randomly selected to represent the clinical diversity of French TB localization. Clinical and demographic data were recorded for each TB patient. The mean age of patients was 36 years old. They came from Africa (44%), Asia (27%), Europe (26%) and America (3%). Strains isolated from extrapulmonary samples were associated with Asian patients, whereas strains isolated from pulmonary samples were associated with European patients. We observed a high level of lineage diversity in line with the known worldwide diversity. Interestingly, lineage 3 was associated with lymph node TB. Additionally, the sensitivity of WGS for predicting resistance was 100% for rifampicin, isoniazid and ethambutol and 66.7% for pyrazinamide. The global concordance with drug-susceptibility testing using the phenotypic approach was 97%. In microbiology laboratories, WGS turns out to be an essential tool for better understanding local TB epidemiology, with direct access to circulating lineage identification and to drug susceptibilities to first- and second-line anti-TB drugs.
- Published
- 2022
- Full Text
- View/download PDF
37. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
- Author
-
Guglielmetti L, Günther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL, Goletti D, Jankovic M, Kuksa L, Maurer FP, Méchaï F, Tiberi S, van Leth F, Veziris N, and Lange C
- Subjects
- Antitubercular Agents therapeutic use, Drug Therapy, Combination, Europe, Humans, Rifampin analogs & derivatives, Rifampin therapeutic use, Antibiotics, Antitubercular therapeutic use, Tuberculosis drug therapy, Tuberculosis epidemiology
- Abstract
Competing Interests: Conflict of interest: L. Guglielmetti is the co-principal investigator of two MSF-sponsored clinical trials testing shorter MDR-TB regimens, and has no other competing interests to disclose. All other authors have no competing interests.
- Published
- 2022
- Full Text
- View/download PDF
38. Invasive Rhinosinusitis Caused by Alternaria infectoria in a Patient with Autosomal Recessive CARD9 Deficiency and a Review of the Literature.
- Author
-
Paccoud O, Vignier N, Boui M, Migaud M, Vironneau P, Kania R, Méchaï F, Brun S, Alanio A, Tauziède-Espariat A, Adle-Biassette H, Ouedraogo E, Bustamante J, Bouchaud O, Casanova JL, Puel A, and Lanternier F
- Abstract
Phaeohyphomycoses comprise a heterogeneous group of fungal infections caused by dematiaceous fungi and have primarily been reported in patients with underlying acquired immunodeficiencies, such as hematological malignancies or solid-organ transplants. Over the past decade, a growing number of patients with phaeohyphomycosis but otherwise healthy were reported with autosomal recessive (AR) CARD9 deficiency. We report a 28-year-old woman who presented with invasive rhinosinusitis caused by Alternaria infectoria . Following a candidate gene sequencing approach, we identified a biallelic loss-of-function mutation of CARD9, thereby further broadening the spectrum of invasive fungal diseases found in patients with inherited CARD9 deficiency. In addition, we reviewed 17 other cases of phaeohyphomycosis associated with AR CARD9 deficiency. Physicians should maintain a high degree of suspicion for inborn errors of immunity, namely CARD9 deficiency, when caring for previously healthy patients with phaeohyphomycosis, regardless of age at first presentation.
- Published
- 2022
- Full Text
- View/download PDF
39. Asymptomatic bacteriuria before biotherapy for rheumatic diseases: Shall we treat?
- Author
-
Hassold N, Saidenberg N, Sigaux J, Lacroix M, Cruaud P, Walewski V, Bouchaud O, and Méchaï F
- Subjects
- Biological Therapy, Humans, Bacteriuria diagnosis, Bacteriuria drug therapy, Rheumatic Diseases drug therapy
- Published
- 2022
- Full Text
- View/download PDF
40. [ 18 F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis.
- Author
-
Sarda-Mantel L, Kaoutar J, Alfaiate T, Lopes A, Paycha F, Benali K, Mikail N, Soussan M, Lemarignier C, Méchaï F, Nagat SL, Montravers F, Deradji O, Durand E, Goulenok T, Ponscarme D, Yéni P, Laouénan C, and Rioux C
- Abstract
Objective: In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [
18 F]FDG-PET for this purpose. Methods: Forty-two patients out of 55 included patients could be analyzed. Additionally to usual biological, histological and morphological explorations, [18 F]FDG-PET was performed at diagnosis (PET1), at the end of treatment (PET2), indeed 6 months later. Then patients were followed until 12 months after end of prescribed treatment. Results: PET1 was positive in 97.6% of patients and discovered unknown injured sites in 52.7% of cases. PET2 was positive in 83.3% of uncured patients, and in 82.3% of cured patients. The sum and mean value of SUVmax measured in PET/CT lesions decreased between PET1 and PET2 in all patients. Mean value of SUVmax (MSUV) and sum value of SUVmax on PET2 showed the highest AUC on ROC curves for the diagnosis of healing at the end of prescribed treatment; MSUV 3.5 on PET2 had a sensitivity of 76.5% and a specificity of 80.0% to affirm healing at the end of prescribed treatment. Conclusions: [18 F]FDG-PET/CT was useful at diagnosis, discovering unknown lesions in 52.7% of cases. MSUV on PET2 was the best criteria to affirm healing at the end of prescribed treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Sarda-Mantel, Kaoutar, Alfaiate, Lopes, Paycha, Benali, Mikail, Soussan, Lemarignier, Méchaï, Nagat, Montravers, Deradji, Durand, Goulenok, Ponscarme, Yéni, Laouénan and Rioux.)- Published
- 2021
- Full Text
- View/download PDF
41. Pulmonary tuberculosis: Evaluation of current diagnostic strategy.
- Author
-
Gressens SB, Billard-Pomares T, Leboité H, Cruaud P, Bouchaud O, Carbonnelle E, and Méchaï F
- Subjects
- Adult, Algorithms, Early Diagnosis, Female, France, Humans, Male, Middle Aged, Mycobacterium tuberculosis isolation & purification, Nucleic Acid Amplification Techniques methods, Retrospective Studies, Sensitivity and Specificity, Specimen Handling, Sputum microbiology, Tuberculosis, Pulmonary diagnosis
- Abstract
Objective: To identify tools that will result in faster diagnosis, making the current pulmonary tuberculosis strategy more efficient., Patients and Methods: A 4-year (2015-2018) retrospective study. The gold standard for diagnosis was a positive culture from a respiratory specimen. All sputum, fibroscopy and post-fibroscopy specimens (for smear negative patients) were collected. Each specimen was analyzed through smear examination and culture. All nucleic acid amplification testing results were included. Analyses looked at the incremental yield of positive cases of each successive specimen collection, and time to diagnosis., Results: A total of 354 patients had at least one positive culture. Sputum allowed a diagnosis in 92% of cases (including a gain in sensitivity of around 7% for the third sputum specimen), with 160 smear-positive patients (45%). Among smear-negative patients, 109 underwent a fibroscopy procedure (culture sensitivity of 75%), and 59 had a post-fibroscopy specimen collected, which together identified the rest of the patients (8%). Molecular testing was used in 237 specimens. Median time to diagnosis was 11 days, which was significantly reduced among smear-negative patients when molecular testing was used (P<0.001). Shortening the delay between sputum specimen collections did not alter procedure sensitivity., Conclusions: We identified several aspects of the French tuberculosis diagnosis algorithm that could be improved, and posed the basis for a prospective study. Centers in higher incidence areas could benefit from a dedicated, predefined procedure exploring suspicions of tuberculosis. A high suspicion score of tuberculosis could drive the reasoned use of molecular testing in such settings., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Hemorrhagic cystitis from BK virus in a patient with AIDS.
- Author
-
Hassold N, Baltes V, Martin A, Méchaï F, Bouchaud O, and Cordel H
- Subjects
- Humans, Acquired Immunodeficiency Syndrome complications, BK Virus, Cystitis complications, HIV Infections complications, Hematopoietic Stem Cell Transplantation, Polyomavirus Infections complications
- Published
- 2021
- Full Text
- View/download PDF
43. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?
- Author
-
Méchaï F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, Santin M, Goletti D, and Cambau E
- Subjects
- Developed Countries, Europe, Humans, Sputum, Tuberculosis diagnosis, Tuberculosis, Pulmonary
- Abstract
Objectives: To evaluate and compare practices regarding the diagnosis, isolation measures, and treatment of tuberculosis (TB) in high-income countries and mainly in Europe. Materials and Methods: A survey was conducted from November 2018 to April 2019 within the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). The practices observed were compared to the main international guidelines. Results: Among 136 ESGMYC members, 64 (17 countries) responded to the questionnaire. In their practice, two (20.7%) or three sputum samples (79.3%) were collected for the diagnosis of pulmonary TB, alternatively induced sputum ( n = 37, 67.2%), bronchoscopy (34, 58.6%), and gastric aspirates (15, 25.9%). Nucleic acid amplification tests (NAATs) were performed by 41 (64%) respondents whatever the smear result and by 47 (73%) in case of smear-positive specimens. NAAT and adenosine deaminase measurement were used for extrapulmonary TB diagnosis in 83.6 and 40.4% of cases, respectively. For isolation duration, 21 respondents (42.9%) were keeping isolation until smear negativity. An initial treatment without ethambutol was offered by 14% ( n = 9) of respondents. Corticosteroid therapy, cerebrospinal fluid opening pressure testing, and repeated lumbar puncture were carried out for central nervous system TB by 79.6, 51.9, and 46.3% of the respondents, respectively. For patients with human immunodeficiency virus-TB coinfection, the preferred antiretroviral therapy included dolutegravir 50 mg twice a day (56.8%). Comparing with the recommendations of the main guidelines, the practices are not totally consistent. Conclusion: This study shows heterogeneous practices, particularly for diagnosis, and isolation, although rapid molecular testing is implemented in most centers. More standardization might be needed., (Copyright © 2020 Méchaï, Cordel, Guglielmetti, Aubry, Jankovic, Viveiros, Santin, Goletti and Cambau.)
- Published
- 2020
- Full Text
- View/download PDF
44. Management and treatment of uncomplicated imported malaria in adults. Update of the French malaria clinical guidelines.
- Author
-
Epelboin L, Rapp C, Faucher JF, Méchaï F, Bottieau E, Matheron S, Malvy D, and Caumes E
- Subjects
- Adult, Communicable Diseases, Imported prevention & control, France, Humans, Malaria prevention & control, Practice Guidelines as Topic, Communicable Diseases, Imported diagnosis, Communicable Diseases, Imported therapy, Malaria diagnosis, Malaria therapy
- Published
- 2020
- Full Text
- View/download PDF
45. Tuberculous meningitis: Challenges in diagnosis and management.
- Author
-
Méchaï F and Bouchaud O
- Subjects
- Humans, Tuberculosis, Meningeal diagnosis, Tuberculosis, Meningeal therapy
- Abstract
Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis. In 2017, approximately 10 million people developed TB worldwide, of whom more than 100,000 new cases of TBM are estimated to occur per year. In patients who are co-infected with HIV-1, TBM has a mortality approaching 50%. Diagnosis of TBM is often delayed by the insensitive and lengthy culture technique required for disease confirmation. GeneXpert represents the most significant advance in TBM diagnostics over the past decade, but it lacks sensitivity and cannot be used to rule out the diagnosis. Higher volume of cerebrospinal fluid (CSF) seems to be interesting to improve the diagnosis performances. New rapid and accurate diagnostic tools are necessary. Better advances have been made concerning the anti-tuberculosis chemotherapy of TBM, with the publication of clinical trials and pharmacokinetic studies exploring the use of higher rifampicin doses and fluoroquinolones. The rise of drug-resistant TBM is another challenge for management because TBM caused by multidrug resistant organisms results in death or severe disability in almost all sufferers., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
46. [Pulmonary tuberculosis: Radiological evolution of broncho-pulmonary lesions at the end of treatment].
- Author
-
Méchaï F, Fock-Yee C, Bouvry D, Raffetin A, Bouchaud O, Brauner M, and Brillet PY
- Subjects
- Adolescent, Adult, Aged, Bronchi pathology, Female, France, Humans, Lung pathology, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary pathology, Young Adult, Bronchi diagnostic imaging, Lung diagnostic imaging, Tomography, X-Ray Computed methods, Tuberculosis, Pulmonary diagnostic imaging
- Abstract
Objectives: To describe the residual broncho-pulmonary lesions and evaluate the role of CT scanning at the end of treatment of pulmonary tuberculosis., Materials and Methods: Analysis of the initial and end of treatment CT scans of 56 patients with pulmonary tuberculosis according to a reading grid including parenchymatous and airways lesions. The CT data at the end of treatment were analysed in relation to the clinical and microbiological data, and the original CT scan., Results: Active lesions (thick walled cavities and/or centrilobular micronodules) persisted in 24 patients (43%) after a mean treatment period of 7 months. The persistence of these signs of activity was correlated with the initial presence of a cavitary syndrome (p=0.027), with predominant sub-segmentary bronchial involvement, with extensive micronodular spread (p=0.024) and with bronchiectasis (p=0.04). These residual lesions were not associated with an increased risk of relapse., Conclusion: The persistence of signs of activity on the CT scan at the end of treatment of tuberculosis do not necessarily correspond to an absence of cure but to a radiological delay. This imaging is nevertheless useful to make an assessment of any subsequent changes in the bronchial tree and to estimate the risk of later complications., (Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Clinical Assessment of a Nocardia PCR-Based Assay for Diagnosis of Nocardiosis.
- Author
-
Rouzaud C, Rodriguez-Nava V, Catherinot E, Méchaï F, Bergeron E, Farfour E, Scemla A, Poirée S, Delavaud C, Mathieu D, Durupt S, Larosa F, Lengelé JP, Christophe JL, Suarez F, Lortholary O, and Lebeaux D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Colony Count, Microbial, Female, Hospitalization, Humans, Immunocompromised Host, Lung Diseases diagnosis, Lung Diseases microbiology, Male, Middle Aged, Nocardia isolation & purification, Opportunistic Infections microbiology, RNA, Ribosomal, 16S, Sensitivity and Specificity, Young Adult, Nocardia Infections diagnosis, Opportunistic Infections diagnosis, Polymerase Chain Reaction methods
- Abstract
The diagnosis of nocardiosis, a severe opportunistic infection, is challenging. We assessed the specificity and sensitivity of a 16S rRNA Nocardia PCR-based assay performed on clinical samples. In this multicenter study (January 2014 to April 2015), patients who were admitted to three hospitals and had an underlying condition favoring nocardiosis, clinical and radiological signs consistent with nocardiosis, and a Nocardia PCR assay result for a clinical sample were included. Patients were classified as negative control (NC) (negative Nocardia culture results and proven alternative diagnosis or improvement at 6 months without anti- Nocardia treatment), positive control (PC) (positive Nocardia culture results), or probable nocardiosis (positive Nocardia PCR results, negative Nocardia culture results, and no alternative diagnosis). Sixty-eight patients were included; 47 were classified as NC, 8 as PC, and 13 as probable nocardiosis. PCR results were negative for 35/47 NC patients (74%). For the 12 NC patients with positive PCR results, the PCR assay had been performed with respiratory samples. These NC patients had chronic bronchopulmonary disease more frequently than did the NC patients with negative PCR results (8/12 patients [67%] versus 11/35 patients [31%]; P = 0.044). PCR results were positive for 7/8 PC patients (88%). There were 13 cases of probable nocardiosis, diagnosed solely using the PCR results; 9 of those patients (69%) had lung involvement (consolidation or nodule). Nocardia PCR testing had a specificity of 74% and a sensitivity of 88% for the diagnosis of nocardiosis. Nocardia PCR testing may be helpful for the diagnosis of nocardiosis in immunocompromised patients but interpretation of PCR results from respiratory samples is difficult, because the PCR assay may also detect colonization., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
48. Active pulmonary tuberculosis: Role for amikacin in early treatment.
- Author
-
Méchaï F, Figoni J, Leblanc C, Gousseff M, Vignier N, and Bouchaud O
- Subjects
- Adult, Amikacin administration & dosage, Antitubercular Agents administration & dosage, Bacterial Load, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis isolation & purification, Patient Isolation, Sputum microbiology, Time Factors, Amikacin therapeutic use, Antitubercular Agents therapeutic use, Tuberculosis, Pulmonary drug therapy
- Abstract
Objective: To evaluate the efficacy of amikacin on sputum conversion during initial sputum smear positive tuberculosis treatment., Material and Methods: Single-center observational cohort study (2012-2013) evaluating time to sputum smear conversion with standard treatment (ST) versus standard treatment+amikacin (IV 15mg/kg/day) for seven days (STamK)., Results: Forty-five patients were included. Median time to smear negative samples was 26.5 days (14-56) for the 30 (66.7%) patients included in the ST group and 48 days (19.5-69.5) for the 15 patients (33.3%) included in the STamK group (P=0.76). Time to negative culture was only known for 27 patients (61.4%): 47.5 days (26-58) for 18 patients in the ST group and 40 days (14-77) for nine patients in the STamK group., Conclusion: Despite our small sample size, the addition of amikacin in active tuberculosis treatment did not seem to impact time to smear conversion or period of contagiousness., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. Lemierre's syndrome: An unusual presentation.
- Author
-
Medina F, Tatay M, Smati M, Aoun O, Tankovic J, Bouchaud O, and Méchaï F
- Subjects
- Amoxicillin-Potassium Clavulanate Combination therapeutic use, Anti-Bacterial Agents therapeutic use, Clindamycin therapeutic use, Drug Therapy, Combination, Embolism diagnostic imaging, Embolism etiology, Female, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections microbiology, Headache etiology, Humans, Lemierre Syndrome complications, Lemierre Syndrome microbiology, Myalgia etiology, Retropharyngeal Abscess etiology, Rifampin therapeutic use, Spondylitis diagnostic imaging, Spondylitis drug therapy, Tomography, X-Ray Computed, Young Adult, Cervical Vertebrae microbiology, Gram-Positive Bacterial Infections complications, Lemierre Syndrome diagnosis, Peptostreptococcus isolation & purification, Spondylitis etiology
- Published
- 2015
- Full Text
- View/download PDF
50. Carnobacterium divergens Bacteremia in woman.
- Author
-
Smati M, Palacios C, Cohen Y, Méchaï F, Tankovic J, Le Flèche-Mateos A, Picard B, and Gonzalez F
- Subjects
- Anti-Bacterial Agents therapeutic use, Bacterial Typing Techniques, Carnobacterium genetics, Female, Gram-Positive Bacterial Infections drug therapy, Humans, Middle Aged, Treatment Outcome, Bacteremia, Carnobacterium isolation & purification, Gram-Positive Bacterial Infections diagnosis, Gram-Positive Bacterial Infections microbiology
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.